Patient characteristics: N = 276.
| CHARACTERISTIC | VALUE |
|---|---|
| Male sex, n (%) | 157 (56.9) |
| Median (IQR) age, y* | 60 (47–68) |
| Time of warfarin administration, n (%) | |
| • Morning | 42 (15.2) |
| • Evening | 228 (82.6) |
| • Not stated | 6 (2.2) |
| Target INR range, n (%) | |
| • 2.0–3.0 | 155 (56.2) |
| • 2.5–3.5 | 110 (39.9) |
| • Other | 11 (4.0) |
| History of > 1 critical INR result, n (%) | 136 (49.3) |
| Antiplatelet therapy, n (%)† | 132 (47.8) |
| Indication for anticoagulation, n (%)‡ | |
| • Mechanical heart valve | 128 (46.4) |
| -Aortic | 62 (48.4) |
| -Mitral | 51 (39.8) |
| -Aortic and mitral | 15 (11.7) |
| • Venous thromboembolism | 65 (23.6) |
| • Atrial fibrillation | 64 (23.2) |
| Concurrent medical conditions, n (%)‡ | |
| • Atrial fibrillation | 116 (42.0) |
| • Hypertension | 112 (40.6) |
| • Heart failure | 83 (30.1) |
| • Coronary artery disease | 70 (25.4) |
| • Stroke or TIA | 67 (24.3) |
| • Diabetes (type 1 or 2) | 49 (17.8) |
| • Thyroid disorder | 41 (14.9) |
| • Renal dysfunction§ | 30 (10.9) |
INR—international normalized ratio, IQR—interquartile range, TIA—transient ischemic attack.
↵* At the time of the most recent critical INR result included in the study.
↵† Includes 1 patient taking dual antiplatelet therapy.
↵‡ Indications and concurrent conditions with < 10% occurrence are not reported.
↵§ Defined as dialysis or serum creatinine level > 200 µmol/L.